← Leaderboards
George R Painter
Chimerix, Inc.
$36,309,505
Attributed
$36,309,505
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.6M · FY2005–07$10M$7.5M$5M$2.5M$0
'05
'06
'07
Funding mix
By agency
NIH$36,309,505 · 1
By mechanism
U01$36,309,505 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Adverse Effect”
- Elizabeth A Thom · George Washington University$121,387,653
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- John M Lachin · George Washington University$118,921,924
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,372,214
- Myron S Cohen · Family Health International$101,800,876
Research focus
Drug Adverse EffectCidofovirMacaca FascicularisSmallpox VirusChemical AggregateAntiviral AgentsDrug Screening /EvaluationBioterrorism /Chemical WarfareLaboratory MouseClinical Trial Phase IDrug Design /Synthesis /ProductionBlood ChemistryPharmacokineticsPolymerase Chain ReactionPoxviridae DiseaseLiquid Chromatography Mass SpectrometryHuman SubjectNonhuman Therapy EvaluationClinical ResearchHuman Therapy EvaluationDrug InteractionsCooperative StudyClearance RateOral Administration
Grant awards (5)
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT$8,448,207
U01 · FY2007 · AI · contact PI
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT$8,630,636
U01 · FY2006 · AI · contact PI
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT$8,477,202
U01 · FY2005 · AI
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT$7,747,639
U01 · FY2004 · AI
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT$3,005,821
U01 · FY2003 · AI